VTGN News and Press, VistaGen Therapeutics Inc. From 04/12/22

VistaGen Therapeutics (NASDAQ:VTGN) and AffaMed Therapeutics said they have completed regulatory preparations to begin a phase 3 trial of VistaGen’s nasal spray PH94B (AM005) for the acute treatment of anxiety in adults with social anxiety disorder (SAD), in the U.S. and China. Th...

Companies plan to initiate the global study of PH94B for the acute treatment of social anxiety disorder (SAD) in the second half of 2022 Trial designed to support commercialization of PH94B in China and other markets outside the U.S. VistaGen Therapeutics, Inc. (Nasd...

VistaGen (NASDAQ: VTGN) , a late clinical-stage, neuro-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, today announced that its Chief Executive O...

SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen), a late clinical-stage, neuro-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression and other centr...

Gainers: Orphazyme ORPH +22%. Y-mAbs Therapeutics YMAB +11%. Oscar Health (NYSE:OSCR) +9%.  Theravance Biopharma TBPH +9%. VistaGen Therapeutics (NASDAQ:VTGN) +8%. Losers: ProQR Therapeutics PRQR -72%. Senseonics SENS -19%. PetVivo P...

VistaGen Therapeutics (NASDAQ: VTGN ), a company developing therapeutics to transform the treatment paradigm for patients suffering from anxiety, depression and other central nervous system disorders, has reported its third-quarter 2022 financial and business status. Highlights of the repor...

VistaGen Therapeutics, Inc. (VTGN) Q3 2022 Earnings Conference Call February 10, 2022 17:00 ET Company Participants Mark Flather - Vice President, Investor Relations Shawn Singh - Chief Executive Officer Jerry Dotson - Chief Financial Officer Mark Smith - Chief Medical Officer Conference Call...

VistaGen Therapeutics press release (NASDAQ:VTGN): Q3 GAAP EPS of -$0.05 beats by $0.02. Revenue of $0.36M (+16.1% Y/Y) beats by $0.11M. At December 31, 2021, the Company had cash and cash equivalents of approximately $83.7 million. For further details see: VistaGen Therapeutics GAAP EP...

Advancing late-stage PH94B clinical program, including: Progress towards topline data readouts for PALISADE-1 and PALISADE-2 Phase 3 trials designed to evaluate PH94B in social anxiety disorder (SAD) that are expected in mid-2022 and second half 2022, respectively; PALIS...

VistaGen (NASDAQ: VTGN) is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders. The company has ann...